Nasdaq

First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259

ROCKVILLE, Md., April 13, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair ...
Pharmabiz

G-treeBNT plans to file IND for phase III trial with RGN-259 in patients with moderate to severe dry eye

RegeneRx Biopharmaceuticals, Inc, and G-treeBNT Co. Ltd, a Korean biotech firm, jointly announced that G-treeBNT is preparing to file an IND and sponsor a phase III clinical trial with RGN-259 (a ...
Pharmabiz

RegeneRx begins phase 3 trial of RGN-259 to treat patients with dry eye

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that the first patients have been enrolled in a phase 3 ...
FierceBiotech

RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

ROCKVILLE, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to ...
Nasdaq

RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259

ROCKVILLE, Md., May 14, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and ...
FierceBiotech

RegeneRx Focuses Immediate Clinical Development on Dry Eye Indication with RGN-259, Provides Update on AMI Phase 2 Study Clinica

RegeneRx Focuses Immediate Clinical Development on Dry Eye Indication with RGN-259, Provides Update on AMI Phase 2 Study Clinical Hold ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc ...